Cardiff Oncology Inc

Cardiff Oncology Inc

Health CarePharmaceuticals & Biotechnology
  • Price (USD)20.75
  • Today's Change0.24 / 1.17%
  • Shares traded1.33m
  • 1 Year change1,448.51%
  • Beta1.8665
Data delayed at least 15 minutes, as of Dec 04 2020 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • CRDF:NAQ price reached a new 52-week high of 25.42 at 09:30 GMT
  • CRDF:NAQ price reached a new 52-week high of 22.69 at 09:35 GMT
  • CRDF:NAQ price moved over +2.24% to 22.41
  • CRDF:NAQ trading volume exceeds daily average by +15.01%
  • CRDF:NAQ price falls below 15-day moving average to 19.44 at 11:30 GMT

Key statistics

On Friday, Cardiff Oncology Inc (CRDF:NAQ) closed at 20.75, -18.63% below its 52-week high of 25.50, set on Dec 01, 2020.
52-week range
0.701Mar 19 202025.50Dec 01 2020
Markit short selling activity
Previous close20.51
Average volume1.07m
Shares outstanding35.32m
Free float35.24m
P/E (TTM)--
Market cap724.51m USD
EPS (TTM)-1.60
Data delayed at least 15 minutes, as of Dec 04 2020 21:00 GMT.
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.